clinical trial · NCT02750618
Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
Kyowa Kirin, Inc.·phase2·completed·n = 13
X-Linked HypophosphatemiaBurosumab
brief summary
The primary objectives of the study are to: * Establish the safety profile of KRN23 for the treatment of XLH in children between 1 and 4 years old * Determine the PD effects of KRN23 treatment on serum phosphorus and other PD markers that reflect the status of phosphate homeostasis in children between 1 and 4 years old with XLH
started
May 5, 2016
primary completion
Apr 20, 2017
completion
Sep 10, 2019
last updated
May 6, 2024
official title
An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol